WO2010055292A2 - Vectors - Google Patents
Vectors Download PDFInfo
- Publication number
- WO2010055292A2 WO2010055292A2 PCT/GB2009/002647 GB2009002647W WO2010055292A2 WO 2010055292 A2 WO2010055292 A2 WO 2010055292A2 GB 2009002647 W GB2009002647 W GB 2009002647W WO 2010055292 A2 WO2010055292 A2 WO 2010055292A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- baculovirus
- recombinant
- bacmid
- expression
- transfer vector
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 50
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 202
- 241000701447 unidentified baculovirus Species 0.000 claims abstract description 131
- 230000014509 gene expression Effects 0.000 claims abstract description 122
- 230000002068 genetic effect Effects 0.000 claims abstract description 51
- 238000012546 transfer Methods 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 110
- 210000004027 cell Anatomy 0.000 claims description 68
- 238000005215 recombination Methods 0.000 claims description 66
- 230000006798 recombination Effects 0.000 claims description 65
- 241000700605 Viruses Species 0.000 claims description 48
- 239000003550 marker Substances 0.000 claims description 44
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 21
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 20
- 101800000385 Transmembrane protein Proteins 0.000 claims description 15
- 230000006801 homologous recombination Effects 0.000 claims description 15
- 238000002744 homologous recombination Methods 0.000 claims description 15
- 101150075620 odv-e56 gene Proteins 0.000 claims description 12
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 101100363961 Escherichia coli (strain K12) rseD gene Proteins 0.000 claims description 5
- -1 iαp2 Proteins 0.000 claims description 4
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 claims description 3
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 claims description 3
- 108010035235 Phleomycins Proteins 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000000007 visual effect Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 description 34
- 230000037431 insertion Effects 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 32
- 108010052090 Renilla Luciferases Proteins 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 101710182846 Polyhedrin Proteins 0.000 description 24
- 241000238631 Hexapoda Species 0.000 description 21
- 108090000331 Firefly luciferases Proteins 0.000 description 20
- 241000588724 Escherichia coli Species 0.000 description 17
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 14
- 206010022000 influenza Diseases 0.000 description 14
- 102000007474 Multiprotein Complexes Human genes 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 241000120506 Bluetongue virus Species 0.000 description 12
- 108010085220 Multiprotein Complexes Proteins 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 229960005091 chloramphenicol Drugs 0.000 description 9
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 101710081079 Minor spike protein H Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 108010051219 Cre recombinase Proteins 0.000 description 6
- 101000653663 Homo sapiens T-complex protein 1 subunit epsilon Proteins 0.000 description 6
- 244000292604 Salvia columbariae Species 0.000 description 6
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 6
- 235000001498 Salvia hispanica Nutrition 0.000 description 6
- 102100029886 T-complex protein 1 subunit epsilon Human genes 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 235000014167 chia Nutrition 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 208000003322 Coinfection Diseases 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 101001022723 Mus musculus Feline leukemia virus subgroup C receptor-related protein 2 Proteins 0.000 description 5
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004186 co-expression Effects 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 4
- 101000837443 Homo sapiens T-complex protein 1 subunit beta Proteins 0.000 description 4
- 102100028679 T-complex protein 1 subunit beta Human genes 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 108010084455 Zeocin Proteins 0.000 description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 238000002439 negative-stain electron microscopy Methods 0.000 description 4
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101150039660 HA gene Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010001267 Protein Subunits Proteins 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 241000242739 Renilla Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 1
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 1
- 101000653469 Homo sapiens T-complex protein 1 subunit zeta Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710134837 Occlusion-derived virus envelope protein E56 Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 102100030664 T-complex protein 1 subunit zeta Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229950006334 apramycin Drugs 0.000 description 1
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14051—Methods of production or purification of viral material
- C12N2710/14052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Definitions
- the present invention relates to a transfer vector for inserting a gene into a genetic locus of a baculovirus sequence.
- the present invention also relates to methods of using the transfer vector and derived bacmids and baculoviruses.
- the baculovirus expression system has been used to express many thousands of proteins in eukaryotic cells for structural and biochemical studies (14). In addition to its ability to express single recombinant proteins the baculovirus system has also been used to co-express multiple proteins that form complexes (15-22). This is important as genome- wide interaction screens are revealing that many critical functions of living cells are carried out by multi- subunit protein complexes (23). Two main strategies have been used to achieve co-expression of proteins using the baculovirus system. The coinfection of cells with two or more viruses each of which expresses one recombinant protein is by far the most common approach (19,24,25).
- rod shaped baculovirus appears quite tolerant of insertions in its genome, genes are transferred to the virus by homologous recombination and the transfer vector must be of a size that is easily manipulated in E. coli. Therefore there is a limit to the number of genes that can be inserted into a transfer vector. In practice this means that it is rarely possible to express more than four proteins from a single locus.
- baculoviruses contain sequences and express proteins that promote homologous recombination (29-32). Therefore viruses that contain large amounts of repeated sequence are prone to rearrangement and recombination (21,33,34).
- the single baculovirus coexpression approach has been modified by insertion of a loxP site at the chiA/cathepsin locus of a bacmid that already contains the Tn7 target at the polyhedrin locus (20).
- This allows insertion of multiple expression cassettes at each of these loci using recombination in E. coli.
- this system relies on the iterative duplication of an expression cassette that has been modified to express different genes there is evidence that inserts into this system are somewhat unstable genetically (21).
- the present invention relates to a method for the efficient expression of multiple recombinant proteins (i.e., non-baculoviral proteins) from a single baculovirus genome.
- the method allows single protein expression cassettes to be inserted efficiently at different loci within the viral genome using the ET recombination system. Furthermore, the method allows for the expression of complexes with numerous subunits.
- Another approach that has been proposed for the production of multiple proteins is the insertion of foreign protein(s) at one genetic locus in baculovirus, then selection of virus expressing that protein and the use of this viral genome to recombine at a second genetic locus to express other proteins (7).
- this approach has hardly ever been used.
- a recent development was to modify the BAC based Tn7 transposon system to insert a LoxP site at a second genetic locus in baculovirus to also allow the insertion of extra genes at this locus in E. coli (8).
- this method still suffers from the problems that repeat sequences from duplication of promoters in the bacterial vectors will mean that the construct is genetically unstable for multiple viral passages and transfer vectors will quickly reach the maximum practical size for manipulation in E. coli.
- the method of the present invention overcomes at least some of the problems inherent in the prior methods, such as genetic 1 instability and the requirement for multiple rounds of recombination.
- the present invention provides a transfer vector for inserting a gene into a genetic locus of a baculovirus sequence comprising: an expression cassette comprising a eukaryotic promoter operably linked to the gene; a bipartite selection cassette comprising:
- the transfer vector of the present invention can be used to efficiently insert a gene into a genetic locus of a baculovirus sequence and to select for the baculovirus sequences that comprise the gene.
- a bipartite selection cassette a substantial increase in identification of positive clones (i.e., baculovirus sequences containing the inserted gene) was obtained compared to selection using a single selection marker.
- This provides a significant advantage over the use of a single selection marker. Only a small number of baculoviruses are transformed and hence the marker is only expressed at very low levels. For example, when the marker is antibiotic resistant only very low levels of antibiotic can be used. This results in the selection of bacterial variants that are resistant to the antibiotic used. Hence some bacteria growing on the plates may not contain the modification.
- Using two positive selection methods overcomes the possibility of such false positive selections.
- the transfer vector of the present invention can be any suitable vector, provided it is capable of recombining with a baculovirus sequence via homologous recombination to insert a gene into the baculovirus sequence.
- Suitable transfer vectors are well known to those skilled in the art. Key features of the transfer vector are discussed further below.
- the gene to be inserted into the baculovirus sequence can be any heterologous gene (i.e., non-baculoviral gene). It is preferred that the heterologous gene encodes a subunit of a protein complex.
- the heterologous gene may encode a viral protein, a component of a receptor or a chaperone complex. It is particularly preferred that the heterologous gene encodes a viral protein that together with other viral proteins can form a virus like particle (VLP).
- VLP virus like particle
- the genetic locus at which the gene is inserted into the baculovirus sequence can be any suitable locus that allows expression of the inserted gene and also does not prevent the ability of the baculovirus sequence from replicating.
- locus used should not affect the ability of baculovirus to infect cells, i.e. replicate or spread from cell to cell.
- loci include the polyhedrin and the plO loci.
- Further additional suitable loci identified by the present inventors include ctx, egt, 39k, or/51, gp37, iap2 and odv-e56.
- the baculovirus sequence can be any suitable baculovirus sequence that can replicate in an insect cell and a prokaryotic cell such as E. coli.
- a prokaryotic cell such as E. coli.
- any viral baculovirus genome that contains a BAC replicon may be used.
- Suitable baculovirus sequences include the AcMNPV bacmid.
- the expression cassette refers to the combination of elements required for expression of the gene. Accordingly, the expression cassette comprises a suitable promoter allowing expression of the encoded gene in eukaryotic cells (i.e., insect cells), and a suitable polyadenylation signal sequence flanking the gene sequence.
- eukaryotic cells i.e., insect cells
- suitable polyadenylation signal sequence flanking the gene sequence.
- promoters include the baculovirus viral late promoters (e.g. p35) or viral very late promoters (e.g. polyhedrin and plO promoters).
- Suitable polyadenylation signal sequences include the tryptophan hydroxylase (Tph) polyadenylation sequence, or polyadenylation sequences from baculovirus genes.
- the expression cassette can comprise more than one gene (e.g., 2, 3 or 4 genes) resulting in the expression of more than one gene. However, generally, it is preferred that the expression cassette comprises a single gene.
- the bipartite selection cassette has been found to improve the identification and isolation of clones that have successfully received the gene.
- the bipartite selection cassette comprises 2 different selectable markers.
- the cassette also comprises any elements required for expression of the markers in a bacterial cell such as one or more bacterial promoters.
- the step of selecting sequences that have received the gene comprises selecting for sequences that comprise both the selectable markers. This selection step is carried out in bacterial cells, e.g., E. coli.
- the selectable markers may be any markers that allow the cells comprising the cassette to be selected.
- the markers may be visible such as a marker that causes the appearance or change of colour of a cell or colony.
- the marker may confer resistance to, for example, an antibiotic.
- the two selectable markers may be the same type of marker, e.g. resistance to two different antibiotics, or different types of marker, e.g. antibiotic resistance and a visual marker.
- the first selectable marker is preferably a visual marker, such as the LacZalpha fragment, which allows cells expressing the Z ⁇ cZalpha fragment to appear blue in the presence of IPTG and X-gal.
- the second selectable marker is preferably any marker that confers antibiotic resistance, such as resistance to chloramphenicol, tetracycline, puromycin, ampicillin, penicillin, apramycin, kanamycin or phleomycin. It is particularly preferred that the second marker confers resistance to phleomycin.
- the bipartite selection cassette is flanked by LoxP recombination sequences. LoxP recombination sequences combine together in the presence of Cre recombinase resulting in the deletion of the intervening sequence. Accordingly, the bipartite selection cassette can be removed enabling the same selectable markers to be used when inserting any additional genes into the baculovirus sequence.
- the LoxP sites are modified to ensure that only a single round of recombination can occur between the sites. Suitable modified LoxP sites are known to those skilled in the art, for example, the Lox66 and Lox71 modified sites.
- sequences flanking the expression and bipartite selection cassettes substantially corresponds with sequences of the genetic locus allowing homologous recombination to occur between the transfer vector and the baculovirus sequence.
- Each flanking sequence is preferably at least 20bp in length, more preferably at least 30bp in length and even more preferably at least 50bp in length, and has a sequence allowing specific recombination with a sequence of the genetic locus.
- the present invention provides a method for producing a recombinant bacmid comprising: bringing a bacmid and the transfer vector according to the first aspect of the present invention together to allow homologous recombination; and selecting for a recombinant bacmid that comprises the bipartite selection cassette.
- the recombinant bacmid can be selected using standard techniques depending on the bipartite selection cassette.
- the method for producing a recombinant bacmid may additionally comprise detecting the presence of the gene in the bacmid or its expression product. Suitable screening techniques can be used depending on the specific gene.
- the method preferably further comprises inducing recombination between the LoxP sites, e.g., by exposing the bacmid to Cre recombinase, to remove the bipartite selection cassette.
- the Cre recombinase is preferably under the control of an inducible promoter, such as the arabinose promoter.
- the method of producing a recombinant bacmid is performed in a prokaryotic cell as a prokaryotic cell based system is easier and quicker to manipulate. It is preferred that the prokaryotic cell based system is conducive to homologous recombination. Such systems include the lambda red recombination system, which is described in European patent application EP-A- 1291420.
- the method of producing the recombinant bacmid is performed in E. coli. It is particularly preferred that the method is performed using E.
- coli cell line EL350 which has both an integrated lambda prophage expressing exo, bet and gam under control of the temperature regulated lambdaPL promoter, and Cre recombinase under control of an arabinose inducible promoter.
- the method of producing the recombinant bacmid can be repeated a number of times so that the bacmid can contain a number of heterologous genes, i.e., 1, 2, 3, 4, 5, 6, 7, 8 or more heterologous genes.
- heterologous genes i.e., 1, 2, 3, 4, 5, 6, 7, 8 or more heterologous genes.
- the present invention provides a recombinant bacmid obtained by the method according to the second aspect of the present invention.
- the bacmid comprises the inserted gene and may also comprise remnants of the LoxP sequences. These remnants may be used as markers to identify the bacmids.
- the bacmid preferably comprises at least 6, 7, 8 or 9 heterologous genes.
- the present invention also provides a method for producing a recombinant baculovirus comprising culturing a eukaryotic cell containing the recombinant bacmid obtained by the method according to the second aspect of the present invention under conditions so that a baculovirus is produced.
- the eukaryotic cells are insect cell, more preferably derived from the insects Spodoptera frugiperda or Trichoplusia ni e.g. (iS/21, S ⁇ or TN 5B-1-4) insect cells.
- the baculovirus can be isolated using standard techniques and the expression of the inserted heterologous gene tested.
- the present invention also provides a recombinant baculovirus obtained by the method according to the fourth aspect of the present invention.
- the present invention also provides a recombinant bacmid or a recombinant baculovirus that expresses a plurality of heterolgous proteins, wherein each protein is expressed from a separate genetic locus of the bacmid or baculovirus. It is further preferred that at least one essential gene is positioned between each genetic locus expressing a heterologous protein. Such an arrangement ensures that if homologous recombination occurs between genetic loci expressing a heterologous gene an essential gene is deleted resulting in a non- viable bacmid or baculovirus.
- the bacmid or baculovirus expresses at least 3, more preferably at least 5 and most preferably at least 8 proteins.
- the proteins are heterolgous, i.e., are not encoded by naturally occurring baculoviruses. It is further preferred that the encoded heterologous proteins are subunits of a protein complex, such as a VLP, a receptor complex or a chaperone complex.
- the separate genetic loci of the recombinant bacmid or baculovirus are selected from ctx, egt, 39k, orf51, gp37, iap2, odv-e56 and pi 0.
- the position of such loci are specifically described with reference to baculovirus AcMNPV in Table 1 below.
- One skilled in the art can easily determine the location of the loci in other baculovirus strains and bacmids using this information.
- the genetic loci referred to above are defined below with reference to the reference accession sequence for AcMNPV (accession number NCOO 1623).
- the present invention also provides a recombinant bacmid or a recombinant baculovirus wherein an expression cassette encoding a heterologous protein is inserted at one or more of the following genetic loci: ctx, egt, 39k, orf51, gp37, iap2and odv- e56.
- the recombinant bacmid or recombinant baculovirus encodes a plurality of proteins, each expression cassette being inserted at a different genetic locus. It is further preferred that the recombinant bacmid or recombinant baculovirus encodes at least 3, more preferably at least 5 and most preferably at least 8 proteins. It is further preferred that the encoded heterologous proteins are subunits of a protein complex, such as a VLP, a receptor complex or a chaperone complex.
- the present invention also provides a transfer vector for inserting a gene into a genetic locus of a baculovirus sequence comprising: an expression cassette comprising a eukaryotic promoter operably linked to the gene; and sequences flanking the expression cassette, wherein the sequences substantially correspond to sequences of the genetic locus within the baculovirus sequence, wherein the genetic locus is selected from: ctx, egt, 39k, or/51, gp37, iap2 ⁇ nd odv-e56.
- the present invention also provides a method for producing a recombinant bacmid comprising: bringing a bacmid and the transfer vector according to the eighth aspect of the present invention together to allow homologous recombination; and selecting for a recombinant bacmid that comprises the expression cassette.
- the present invention also provides a method for producing a recombinant baculovirus comprising producing a recombinant bacmid by the method of the present invention and culturing a eukaryotic cell containing the bacmid so that a baculovirus is produced.
- the present invention also provides a recombinant baculovirus obtained by this method.
- the present invention also provides a cell containing a transfer vector, a bacmid, or a baculovirus according to any aspect of the present invention.
- the present invention also provides a method for producing one or more proteins comprising culturing the recombinant bacmid or baculovirus according to any aspect of the present invention under suitable conditions.
- the one or more proteins are encoded by the one or more genes and may combine to form a protein complex such as a VLP or a chaperone complex.
- the one or more proteins can be isolated using standard techniques well known to those skilled in the art.
- Figure 1 shows an improved selection of recombinants from ET cloning.
- A Cartoon of DNA used for cat and bipartite recombinations. Both constructs had the same baculovirus flanking sequences (AcMNPV), Renilla luciferase expression cassette (Pp35-Rluc-Tph) and loxP sites (LoxP). The bipartite selectable marker also had zeocin resistance gene (ZeoR) and LacZ ⁇ fragment. In the chloramphenicol resistant construct this was replaced with the cat gene.
- B Number of positive bacterial colonies following ET recombination. DNA used for recombination was produced either by PCR or restriction enzyme digest, as indicated.
- Figure 2 shows the selective removal of marker genes.
- PCR products corresponding to the sizes predicted for the parental and recombinant products of the Cre mediated recombination are labeled P and R respectively.
- Figure 3 shows identification of additional sites for expression of recombinant proteins in the AcMNPV genome.
- Firefly luciferase activity showing relative expression of a polyhedrin promoter-firefly luciferase polyhedrin terminator cassette inserted at each locus as indicated. Error bars indicate the standard deviation from 5 replicates for each locus.
- Firefly luciferase was normalised using the Renilla luciferase control expressed from the same genome. Firefly luciferase insertions at the orfl l, v-fgf, pe and orf23 loci were excluded due to Renilla luciferase levels more than 2 logs lower than control virus.
- Virus Ph has firefly luciferase at the polyhedrin locus and Renilla luciferase at the plO locus.
- Virus Ph* has the same plO Renilla luciferase insertion but no firefly luciferase insertion.
- Figure 4 shows expression of influenza Ml from egt and polyhedrin loci.
- Left panel shows Coomassie stained SDS PAGE gel of total protein from cells infected with control baculoviruses (lanes 1 and 4), egt-Ml (lane 2) and YMl-Ml (lane 3). The sizes of protein markers (lane M) are indicated on the left hand side of the gel.
- Right panel shows Western blot of duplicate gel probed with anti-H7N7 antiserum.
- Figure 5 shows co-expression of influenza Ml and HA and formation of VLPs.
- A) Left panel shows Coomassie stained gel of total protein; right panel shows western blot of duplicate gel probed with anti-H7N7 influenza virus serum. Cells were infected with dual baculovirus expressing HA and Ml (lane 1), baculovirus expressing HA only (lane T), cells control (lane 3), baculovirus expressing Ml only (lane 4).
- Figure 6 shows production of baculovirus co-expressing 4 proteins.
- A) Cell lysate from cells infected with baculovirus expressing VP2 (lane 1), VP5 (lane 2), VP3 (lane 3) and VP7 (lane 1)
- Figure 7 shows crystalline plates formed on overexpression of CCT5. Quadrilateral protein aggregates in culture media of very late infections with baculovirus expressing CCT5.
- Figure 8 shows expression of CCT in insect cells.
- A) Coomassie stained cell lysate from cells infected with baculovirus expressing CCT1-CCT8 (lanes 1-8, respectively), cells only (lane 9) or baculovirus coexpressing 7 CCT subunits (lane 10).
- the baculovirus expression system has well established potential for the production of large amounts of correctly folded eukaryotic proteins for enzymatic and structural studies.
- proteins are active within cells as complexes made up of the products of several distinct genes.
- the inventors have developed baculovirus transfer vectors capable of expressing 2, 3, 4 and 5 proteins from the same baculovirus genome.
- the inventors' main goal in the previous studies was to produce a system capable of synthesizing large amounts of viral protein complexes containing non-equimolar amounts of virus encoded proteins for structural and enzymatic studies.
- One of the observations from experience with these systems is that single baculoviruses expressing multiple genes are much more efficient at forming the desired protein complexes than co-infection of insect cells with multiple baculoviruses expressing single genes.
- the inventors have used new technologies to exploit this observation for the production of recombinant baculoviruses expressing multiple proteins for biologically relevant mammalian protein complexes.
- the inventors have adapted and improved new bacterial chromosome engineering technologies for the rapid and efficient production of recombinant baculoviruses expressing multiple proteins simultaneously.
- the new systems developed are 30 times more efficient than conventional processes and allow the routine insertion of genes at any locus within the baculo virus genome.
- These studies have allowed identification of 7 new genetic loci within the baculovirus genome that allow high level expression of recombinant protein.
- the inventors have demonstrated that multiple iterative rounds of recombination can be carried out allowing the generation of virus genomes expressing multiple proteins in a complex from separate single gene insertions.
- the inventors have expressed VLP protein complexes for influenza A (H7 subtype) and bluetongue virus (serotype 1), as well as the 8 subunit mammalian chaperone complex CCT (TCP), that is a focus for cancer studies.
- Multi-locus single gene insertions are achieved in E. coli using lambda red recombination.
- the invention includes the use of baculovirus loci that have not previously been used for multi-protein expression, and the incorporation of selectable markers that can be removed from the baculovirus genome and subsequently reused. Unlike other systems, the recombinant protein genes are not flanked by repeat sequences, improving their genetic stability.
- the transfer vectors contain a region of AcMNPV to target homologous recombination, an expression cassette (AcMNPV promoter, polylinker, polyadenylation signal) and a bacterial selection cassette.
- the AcMNPV promoter used is from either viral late (e.g. p35) or very late (e.g. Polyhedrin, plO) genes.
- the bacterial selection cassette consists of mutant LoxP site - bacterial selectable marker - mutant Lox P site.
- the mutant Lox P sites are variants on the LoxP66 and LoxP71 variants (9).
- the LoxP sites for each selectable marker are designed such that on recombination the marker is deleted destroying the LoxP site that remains.
- Each selectable marker has different LoxP mutant arms so that recombination between different selectable marker genes inserted in the same baculovirus will not occur.
- the original research plan involved the use of homologous recombination in insect cells, or the alternative method of ET recombination in E. coli, to allow efficient insertion of expression cassettes for recombinant proteins at different loci within the baculovirus genome.
- Our preliminary data had suggested that linearization of transfer vector resulted in a significant increase in the recombination frequency (up to -30%) at a locus (plO) that did not have positive selection other than the recombinant protein produced.
- the two systems (ET recombination and insect cell recombination) were considered with regards to their reproducibility and time taken to complete insertion of a recombinant gene in a particular locus and check expression of the resulting protein.
- the ET recombination system was faster, mainly because of reduced time needed to prepare the baculovirus genome for the insertion of genes at a second genetic locus in the baculovirus.
- the number of such markers is limited and each could only be used once. Since one of the goals of the project was to express the mouse CCT (TCPl) complex (8 subunits) the ET recombination approach was adopted as the research priority at an early stage as this system was faster and more able to accommodate multiple genetic insertions.
- PCR primers were designed such that the ends of the PCR products corresponded to the ends of the restriction enzyme released fragments.
- PCR was carried out on bacmid DNA purified from positive colonies.
- One primer was designed to a sequence inside the Zeocin resistance marker and one primer targeted a sequence present only in the bacmid DNA flanking the correct insertion site and not in the transfer DNA.
- PCR product would only be produced where recombination had occurred between the linear DNA used for recombination and the bacmid. 12 separate bacmid DNA samples were tested using this method (Fig. 1C, lanes 1-12), all were positive for the PCR product diagnostic for correctly targeted recombination.
- Cre mediated removal of the selectable marker allows multiple rounds of recombination with the same bipartite selection.
- the bipartite marker system was designed such that the selection cassette was flanked by modified LoxP sites. These sites incorporate both the Iox66 and Iox71 mutations that limit Cre mediated recombination to a single round (1) and a mutation in the spacer reducing homology to wildtype loxP sites.
- incubation of modified bacmid with Cre recombinase results in the removal of the bipartite selectable marker and inactivation of the lox recombination site but leaves behind the baculovirus expression cassette (Fig. 2A).
- Cre recombination was used to remove the bipartite marker from bacmid in which the Renilla luciferase reporter had been inserted. Recombination was achieved in E. coli using the EL350 cell line (2), which has both an integrated lambda prophage expressing exo, bet, and gam under control of the temperature regulated ⁇ PL promoter and Cre recombinase under control of an arabinose inducible promoter.
- EL350 cells containing three of the bacmids modified to incorporate the Renilla luciferase-bipartite selection insert were induced with arabinose then spread on plates containing kanamycin, to select for the bacmid, and X-gal, to screen for colonies that had lost the selectable marker by Cre mediated recombination.
- Bacmid DNA was purified from four putative recombinants and Cre mediated recombination confirmed by PCR using primers flanking the selectable markers (Fig. 2B). All four recombinants had PCR products consistent with the size expected from successful Cre recombination. This was further confirmed by sequencing across the modified loxP site of the 4 recombinants (Fig. 2C).
- the recombinants contained a disabled loxP site that incorporates both the loxP71 and loxP66 mutations and is not competent for further rounds of recombination.
- Cre mediated bacmid recombinants remained viable in insect cells, bacmid DNA was transfected into insect cells and luciferase activity assayed after two passages as before. All recombinants had Renilla luciferase activity that was equivalent to the parental bacmids before Cre recombination (Fig. 2D).
- EXAMPLE 3 Identification of genetic loci in the baculovirus genome suitable for high level expression of heterologous proteins.
- Loci were selected as sites for insertion in these experiments by determining which baculovirus genes are non-essential for virus growth in tissue culture, and whether the arrangement of baculovirus genes at particular loci favoured insertion of an additional expression cassette. Nevertheless, some additional changes were made at some loci, particularly changes that resulted in knock-out of particular baculovirus genes (Fig. 3B). Recombinant viruses were passaged twice in S/21 insect cells and on the third passage cells were harvested at 48 hours post infection, lysed, and assayed for both firefly and Renilla luciferase activities.
- Renilla luciferase activity was used as a marker for virus replication and protein expression as all the recombinants had the same /»35 promoter driven Renilla luciferase cassette in the pi 0 locus. Expression of firefly luciferase at each new locus was compared to a virus carrying firefly luciferase gene at the polyhedrin locus and the same Renilla luciferase reference gene.
- the Renilla luciferase activity was used as a reference to normalise firefly luciferase activity and obtain a measure of relative expression of the firefly luciferase from each locus (Fig. 3D).
- 7 loci ctx, egt, 39k, or ⁇ l, gp37, iap2 and odv-e56
- firefly luciferase activity which was at least 10 fold higher than background and similar to that when the same gene was expressed from the polyhedrin locus (Fig. 3D).
- Two viruses chiA and odv-elS
- Example 3 focused on the use of reporter genes to quantitatively assess the potential of different baculovirus loci to express recombinant protein. To establish whether it is possible to express and recover recombinant protein complexes, three specific complexes were targeted with different numbers of protein subunits. Virus-like particles were produced for
- Influenza (A/seal/Mass/1/80) H7 subtype by co-expression of the viral Ml and HA proteins
- Influenza A VLPs For these experiments all influenza genes were from the SC35M mouse adapted strain derived from the H7N7 (A/seal/Mass/1/80) isolate, obtained from researchers at Philipps University Marburg, Germany. To test whether the multi-locus expression system was able to produce protein complexes with two proteins, the coding sequence for the influenza A Ml protein was initially inserted into the egt locus under the control of the polyhedrin promoter. For comparison, the same gene was inserted into a conventional baculovirus expression vector (pAc-YMl) targeting the polyhedrin locus. Following recombination, both resulting baculoviruses expressed the Ml protein. Levels of expression of the protein from the egt and polyhedrin loci were both significantly higher than for any other viral or cellular protein in baculovirus infected cells when assessed by coomassie stained SDS-PAGE (Fig.4).
- influenza VLPs were isolated from the culture medium of infected cells, purified by density gradient ultracentrifugation and visualised by negative stain EM analysis (Fig. 5B). To ensure that VLPs visualised were indeed influenza, particles were immunogold labeled using antibodies specific for influenza HA (Fig 5C).
- VLP Flu VLP have been widely tested by others and shown to be immunogenic in mice and ferrets. This method of constructing the VLP has the advantage that it is possible to have the baculovirus genome with Ml already pre-integrated and ready for expression. Thus, to make VLP it should only be necessary to perform a single round of recombination to add the HA gene from whatever emerging flu subtype is required for vaccine production. For VLP based flu vaccines this would simplify the necessary cloning and potentially increase the speed with which new types of VLP could be made.
- BTV VLP Unlike influenza, where VLP can be formed by expression of just two proteins, BTV VLP require the co-ordinated expression of four structural proteins (VP2, VP3, VP5 and VP7).
- viruses were produced that expressed each protein singly and the combination of all four BTV structural proteins (Fig. 6).
- One of the advantages of the new system is that viruses expressing single proteins and multiple proteins can be made from the same set of transfer vectors. This facilitates production of control viruses expressing single proteins to act as markers for the position of proteins co-expressed in the full complex.
- Fig. 6C For the BTV VLP a different set of loci were used from those in the influenza example (Fig. 6C).
- the new system was combined with the orfl629 knockout Bacmid described by Zhao et ah, (12) to allow use of a conventional transfer vector at the polyhedrin locus to express one of the subunits of the complex. Formation of VLPs was confirmed by particle morphology under negative stain EM, combined with immunogold labelling for one of the outer capsid proteins (VP5) (Fig. 6D).
- the application of the present invention is not limited to the formation of virus-like particles. Indeed, as many cellular proteins are present in cells as complexes with more than one subunit, the efficient formation of these complexes has application to a range of fields.
- the chaperone complex CCT was chosen. This complex has implications in cancer research and with 8 subunits represents a significant challenge for protein expression. Indeed it would not have been possible to express this complex in the baculovirus system without the vectors and methods of the present invention.
- CCT5 For one of the subunits (CCT5) an unusual phenotype was noted when the protein was over expressed in cells. Crystalline needles were noted inside cells and, late in infection when cells had ruptured, quadrilateral plates of crystalline material were noted in the culture medium (Fig. 7). A purification scheme was generated for this protein and this was supplied with preliminary crystallisation conditions and infected cell material to the collaborator for the CCT part of the project.
- VP2 and VP3 accumulated to lower levels than VP5 and VP7 (Fig. 6A).
- This effect cannot be explained by the position effect of genomic integration since in both the single and quadruple viruses the genes were expressed from the same genetic loci.
- One possible explanation would be that the effect was due to the different promoters that were used for the different genes.
- Both VP5 and VP7 were expressed under control of the plO promoter and VP2 and VP3 were under control of the polyhedrin promoter. This would be consistent with a report in the literature where deletion of the plO gene resulted in increased expression from polyhedrin locus 13.
- the inventors have improved the efficiency of the ET recombination system as applied to baculovirus to the point that it can be used for routine insertion of expression cassettes for recombinant proteins. Furthermore, they have identified seven genetic loci (ctx, egt, 39k, or/51, gp37, iap2 and odv-e56) that can be used for high level expression of protein and demonstrated that multi-protein complexes can be assembled using this system using three examples (influenza A and BTV VLPs, and CCT complex).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009315471A AU2009315471B2 (en) | 2008-11-11 | 2009-11-11 | Baculoviral vectors |
JP2011535164A JP5986381B2 (en) | 2008-11-11 | 2009-11-11 | vector |
CN200980144325.4A CN102245777B (en) | 2008-11-11 | 2009-11-11 | Baculovirus vector |
CA2740714A CA2740714A1 (en) | 2008-11-11 | 2009-11-11 | Vectors |
MX2011004902A MX2011004902A (en) | 2008-11-11 | 2009-11-11 | Baculoviral vectors. |
UAA201106570A UA106733C2 (en) | 2008-11-11 | 2009-11-11 | Expression vector |
BRPI0921907-2A BRPI0921907A2 (en) | 2008-11-11 | 2009-11-11 | A transfer vector for inserting a gene into a genetic site of a baculovirus sequence, methods for producing a recombinant bacmid, a recombinant baculovirus, and one or more proteins, recombinant bacmid, recombinant baculovirus, and cell. |
MX2013008741A MX340956B (en) | 2008-11-11 | 2009-11-11 | Baculoviral vectors. |
EP09748839.9A EP2358883B1 (en) | 2008-11-11 | 2009-11-11 | Baculoviral vectors |
ES09748839.9T ES2616855T3 (en) | 2008-11-11 | 2009-11-11 | Baculoviral Vectors |
US13/128,629 US9212374B2 (en) | 2008-11-11 | 2009-11-11 | Vectors |
RU2011114814/10A RU2569183C2 (en) | 2008-11-11 | 2009-11-11 | Vectors |
ZA2011/03286A ZA201103286B (en) | 2008-11-11 | 2011-05-05 | Baculoviral vectors |
PH12014501252A PH12014501252A1 (en) | 2008-11-11 | 2014-06-04 | Vectors |
US14/953,513 US9777260B2 (en) | 2008-11-11 | 2015-11-30 | Vectors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0820631.0 | 2008-11-11 | ||
GBGB0820631.0A GB0820631D0 (en) | 2008-11-11 | 2008-11-11 | Vectors |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/128,629 A-371-Of-International US9212374B2 (en) | 2008-11-11 | 2009-11-11 | Vectors |
US14/953,513 Division US9777260B2 (en) | 2008-11-11 | 2015-11-30 | Vectors |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010055292A2 true WO2010055292A2 (en) | 2010-05-20 |
WO2010055292A3 WO2010055292A3 (en) | 2010-08-26 |
Family
ID=40139744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2009/002647 WO2010055292A2 (en) | 2008-11-11 | 2009-11-11 | Vectors |
Country Status (20)
Country | Link |
---|---|
US (2) | US9212374B2 (en) |
EP (1) | EP2358883B1 (en) |
JP (2) | JP5986381B2 (en) |
KR (1) | KR20110089420A (en) |
CN (2) | CN105400818A (en) |
AU (1) | AU2009315471B2 (en) |
BR (1) | BRPI0921907A2 (en) |
CA (1) | CA2740714A1 (en) |
CL (2) | CL2011001056A1 (en) |
CO (1) | CO6420360A2 (en) |
ES (1) | ES2616855T3 (en) |
GB (1) | GB0820631D0 (en) |
MX (2) | MX2011004902A (en) |
MY (1) | MY178947A (en) |
PH (1) | PH12014501252A1 (en) |
RU (2) | RU2014145441A (en) |
SG (1) | SG10201509570TA (en) |
UA (1) | UA106733C2 (en) |
WO (1) | WO2010055292A2 (en) |
ZA (2) | ZA201103286B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013014400A1 (en) | 2011-07-27 | 2013-01-31 | Genethon | Baculovirus system for the expression of a gene therapy vector |
RU2590588C1 (en) * | 2015-06-19 | 2016-07-10 | Общество с ограниченной ответственностью "Панацела Лабс" Инновационный центр сколково | Method for production of preparation based on non-replicating viral vector expressing gene of human toll-like receptor and gene of modified protein flagellin |
WO2018024998A1 (en) * | 2016-08-05 | 2018-02-08 | Centre National De La Recherche Scientifique | Baculovirus expression system |
FR3072686A1 (en) * | 2017-10-25 | 2019-04-26 | Centre National De La Recherche Scientifique | BACULOVIRUS EXPRESSION SYSTEM |
EP3693466A4 (en) * | 2018-12-28 | 2020-08-12 | Wuhan Institute Of Physics And Mathematics, Chinese Academy of Sciences | Method and system for preparing recombinant adeno-associated virus, and recombinant bacmid |
US11708585B2 (en) * | 2018-12-28 | 2023-07-25 | Wuhan Institute Of Physics And Mathematics, Chinese Academy Of Sciences | Method, system and recombinant bacmid for preparation of recombinant adeno-associated virus |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0820631D0 (en) | 2008-11-11 | 2008-12-17 | London School Hygiene & Tropical Medicine | Vectors |
EP2654624B1 (en) | 2010-12-23 | 2023-10-04 | Twelve, Inc. | System for mitral valve repair and replacement |
GB201309132D0 (en) * | 2013-05-21 | 2013-07-03 | Biosyntia Aps | Regulatable gene expression |
CN114369624B (en) * | 2021-12-30 | 2023-07-14 | 华南农业大学 | Method for reducing apoptosis of insect cells caused by virus infection |
CN118086400A (en) * | 2024-04-17 | 2024-05-28 | 和元生物技术(上海)股份有限公司 | Nucleic acid molecule, recombinant baculovirus comprising same and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000875A2 (en) * | 2000-06-28 | 2002-01-03 | Protemation, Inc. | Compositions and methods for generating expression vectors through site-specific recombination |
WO2003074714A1 (en) * | 2002-03-05 | 2003-09-12 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
WO2007054250A1 (en) * | 2005-11-08 | 2007-05-18 | Eth Zurich | Recombinant expression of multiprotein complexes using polygenes |
WO2007104979A1 (en) * | 2006-03-15 | 2007-09-20 | London School Of Hygiene & Tropical Medicine | Virus-like particles of rift valley fever virus |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1257184B (en) * | 1992-12-22 | 1996-01-10 | Applied Research Systems | PREPARED FOR ANTI-INFLAMMATORY, ANTI-AGULANT AND ANTI-TUMORAL ACTIVITY |
NZ334604A (en) * | 1996-10-01 | 1999-11-29 | American Cyanamid Co | A DNA molecule containing a baculovirus promoter operable linked to a coding sequnce for an insect-specific toxin; biological insect control agents comprising the altered baculovirus |
US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
EP0999284A1 (en) * | 1998-09-11 | 2000-05-10 | Hoechst Marion Roussel | Method for screening antimycotic substances using essential genes from c.albicans, and said genes |
WO2001094571A1 (en) * | 2000-06-08 | 2001-12-13 | Mitsubishi Pharma Corporation | Expression vector enabling screening of cells with high expression of recombinant protein, transformant with high expression of recombinant protein and utilization thereof |
JP4024525B2 (en) * | 2001-11-21 | 2007-12-19 | 独立行政法人科学技術振興機構 | Fusion protein consisting of two different selectable markers |
WO2003093426A2 (en) * | 2002-05-02 | 2003-11-13 | University Of North Carolina At Chapel Hill | In vitro mutagenesis, phenotyping, and gene mapping |
MXPA05003382A (en) * | 2002-10-04 | 2005-06-22 | Du Pont | Process for the biological production of 1,3-propanediol with high yield. |
JP4597188B2 (en) * | 2004-03-09 | 2010-12-15 | アイトゲネシシェ・テヒニーシェ・ホッホシューレ・チューリッヒ | New expression tools for multiprotein applications |
FR2877013A1 (en) * | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | INDENTIFICATION OF A JAK2 MUTATION INVOLVED IN THE VAQUEZ POLYGLOBULIA |
GB0820631D0 (en) | 2008-11-11 | 2008-12-17 | London School Hygiene & Tropical Medicine | Vectors |
-
2008
- 2008-11-11 GB GBGB0820631.0A patent/GB0820631D0/en not_active Ceased
-
2009
- 2009-11-11 KR KR1020117013218A patent/KR20110089420A/en not_active Application Discontinuation
- 2009-11-11 CA CA2740714A patent/CA2740714A1/en not_active Abandoned
- 2009-11-11 JP JP2011535164A patent/JP5986381B2/en not_active Expired - Fee Related
- 2009-11-11 WO PCT/GB2009/002647 patent/WO2010055292A2/en active Application Filing
- 2009-11-11 CN CN201510701296.4A patent/CN105400818A/en active Pending
- 2009-11-11 MX MX2011004902A patent/MX2011004902A/en active IP Right Grant
- 2009-11-11 US US13/128,629 patent/US9212374B2/en not_active Expired - Fee Related
- 2009-11-11 BR BRPI0921907-2A patent/BRPI0921907A2/en not_active Application Discontinuation
- 2009-11-11 RU RU2014145441/10A patent/RU2014145441A/en not_active Application Discontinuation
- 2009-11-11 MX MX2013008741A patent/MX340956B/en unknown
- 2009-11-11 EP EP09748839.9A patent/EP2358883B1/en active Active
- 2009-11-11 MY MYPI2011002077A patent/MY178947A/en unknown
- 2009-11-11 AU AU2009315471A patent/AU2009315471B2/en not_active Ceased
- 2009-11-11 UA UAA201106570A patent/UA106733C2/en unknown
- 2009-11-11 SG SG10201509570TA patent/SG10201509570TA/en unknown
- 2009-11-11 ES ES09748839.9T patent/ES2616855T3/en active Active
- 2009-11-11 CN CN200980144325.4A patent/CN102245777B/en not_active Expired - Fee Related
- 2009-11-11 RU RU2011114814/10A patent/RU2569183C2/en not_active IP Right Cessation
-
2011
- 2011-05-05 ZA ZA2011/03286A patent/ZA201103286B/en unknown
- 2011-05-10 CL CL2011001056A patent/CL2011001056A1/en unknown
- 2011-06-10 CO CO11072225A patent/CO6420360A2/en not_active Application Discontinuation
-
2012
- 2012-05-30 ZA ZA2012/03945A patent/ZA201203945B/en unknown
-
2014
- 2014-06-04 PH PH12014501252A patent/PH12014501252A1/en unknown
-
2015
- 2015-01-14 CL CL2015000113A patent/CL2015000113A1/en unknown
- 2015-11-30 US US14/953,513 patent/US9777260B2/en active Active
- 2015-12-07 JP JP2015238440A patent/JP2016101164A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000875A2 (en) * | 2000-06-28 | 2002-01-03 | Protemation, Inc. | Compositions and methods for generating expression vectors through site-specific recombination |
WO2003074714A1 (en) * | 2002-03-05 | 2003-09-12 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
WO2007054250A1 (en) * | 2005-11-08 | 2007-05-18 | Eth Zurich | Recombinant expression of multiprotein complexes using polygenes |
WO2007104979A1 (en) * | 2006-03-15 | 2007-09-20 | London School Of Hygiene & Tropical Medicine | Virus-like particles of rift valley fever virus |
Non-Patent Citations (5)
Title |
---|
BERGER I ET AL: "Baculovirus expression system for heterologous multiprotein complexes" NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 22, no. 12, 1 December 2004 (2004-12-01), pages 1583-1587, XP002323546 ISSN: 1087-0156 * |
CICCARONE ET AL: "Generation of Recombinant Baculovirus DNA in E. coli Using Baculovirus Shuttle Vector" METHODS IN MOLECULAR MEDICINE, HUMANA PRESS, TOTOWA, NJ, US, vol. 13, 1 January 1997 (1997-01-01), pages 213-235, XP009128928 ISSN: 1543-1894 * |
FITZGERALD DANIEL J ET AL: "PROTEIN COMPLEX EXPRESSION BY USING MULTIGENE BACULOVIRAL VECTORS" NATURE METHODS, NATURE PUBLISHING GROUP, GB, vol. 3, no. 12, 1 December 2006 (2006-12-01), pages 1021-1032, XP009080415 ISSN: 1548-7091 * |
NOAD ROB J ET AL: "Multigene expression of protein complexes by iterative modification of genomic Bacmid DNA" BMC MOLECULAR BIOLOGY, BIOMED CENTRAL LTD, GB, vol. 10, no. 1, 2 September 2009 (2009-09-02), page 87, XP021056445 ISSN: 1471-2199 * |
See also references of EP2358883A2 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013014400A1 (en) | 2011-07-27 | 2013-01-31 | Genethon | Baculovirus system for the expression of a gene therapy vector |
FR2978456A1 (en) | 2011-07-27 | 2013-02-01 | Genethon | BACULOVIRAL SYSTEM FOR THE EXPRESSION OF A GENE THERAPEUTIC VECTOR |
RU2590588C1 (en) * | 2015-06-19 | 2016-07-10 | Общество с ограниченной ответственностью "Панацела Лабс" Инновационный центр сколково | Method for production of preparation based on non-replicating viral vector expressing gene of human toll-like receptor and gene of modified protein flagellin |
WO2016204644A1 (en) * | 2015-06-19 | 2016-12-22 | Общество С Ограниченной Ответственностью "Панацела Лабс" | Method of producing a drug based on a non-replicating viral vector expressing a human toll-like receptor gene and a modified flagellin gene |
WO2018024998A1 (en) * | 2016-08-05 | 2018-02-08 | Centre National De La Recherche Scientifique | Baculovirus expression system |
FR3054841A1 (en) * | 2016-08-05 | 2018-02-09 | Centre National De La Recherche Scientifique | BACULOVIRUS EXPRESSION SYSTEM |
EP4151648A1 (en) * | 2016-08-05 | 2023-03-22 | Centre National de la Recherche Scientifique (CNRS) | Baculovirus expression system |
FR3072686A1 (en) * | 2017-10-25 | 2019-04-26 | Centre National De La Recherche Scientifique | BACULOVIRUS EXPRESSION SYSTEM |
WO2019081858A1 (en) * | 2017-10-25 | 2019-05-02 | Centre National De La Recherche Scientifique (Cnrs) | Baculovirus expression system |
EP3693466A4 (en) * | 2018-12-28 | 2020-08-12 | Wuhan Institute Of Physics And Mathematics, Chinese Academy of Sciences | Method and system for preparing recombinant adeno-associated virus, and recombinant bacmid |
US11708585B2 (en) * | 2018-12-28 | 2023-07-25 | Wuhan Institute Of Physics And Mathematics, Chinese Academy Of Sciences | Method, system and recombinant bacmid for preparation of recombinant adeno-associated virus |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9777260B2 (en) | Vectors | |
Fraser et al. | Assay for movement of Lepidopteran transposon IFP2 in insect cells using a baculovirus genome as a target DNA | |
Vanarsdall et al. | Characterization of the role of very late expression factor 1 in baculovirus capsid structure and DNA processing | |
Li et al. | vlf-1 deletion brought Ac M NPV to defect in nucleocapsid formation | |
Ke et al. | Autographa californica multiple nucleopolyhedrovirus ac66 is required for the efficient egress of nucleocapsids from the nucleus, general synthesis of preoccluded virions and occlusion body formation | |
Xiang et al. | The Bombyx mori nucleopolyhedrovirus (BmNPV) ODV-E56 envelope protein is also a per os infectivity factor | |
JP2016509484A (en) | Improved baculovirus expression system and production method thereof | |
Noad et al. | Multigene expression of protein complexes by iterative modification of genomic Bacmid DNA | |
Okano et al. | A baculovirus alkaline nuclease knockout construct produces fragmented DNA and aberrant capsids | |
Bischoff et al. | Phenotypic and genetic analysis of Lymantria dispar nucleopolyhedrovirus few polyhedra mutants: mutations in the 25K FP gene may be caused by DNA replication errors | |
Liu et al. | A highly efficient and simple construction strategy for producing recombinant baculovirus Bombyx mori nucleopolyhedrovirus | |
guang Yao et al. | A novel economic method for high throughput production of recombinant baculovirus by infecting insect cells with Bacmid-containing diminopimelate-auxotrophic Escherichia coli | |
Roy et al. | Use of bacterial artificial chromosomes in baculovirus research and recombinant protein expression: current trends and future perspectives | |
WO2023070873A1 (en) | Method for preparing sars-cov-2 virus-like particles and use of sars-cov-2 virus-like particles | |
KR101384513B1 (en) | Infectious cDNA clones of Foot-and-mouth disease virus of type O and the complete sequences of the clones | |
Wang et al. | Cloning of complete genomes of large dsDNA viruses by in vitro transposition of an F factor containing transposon | |
AU2014218463A1 (en) | Baculoviral vectors | |
Yang et al. | Characterization of Bombyx mori nucleopolyhedrovirus with a deletion of bm118 | |
Yao et al. | Construction of recombinant vaccinia viruses using leporipoxvirus-catalyzed recombination and reactivation of orthopoxvirus DNA | |
US9909106B2 (en) | Recombinant baculovirus expression vector and cell | |
KR101223577B1 (en) | A recombinant virus bEasyBac and baculovirus expression vector system using the same | |
US6806064B2 (en) | Baculovirus enhancer-like sequence | |
JP2003517811A5 (en) | ||
KR101233081B1 (en) | A recombinant virus bEasyBac and baculovirus expression vector system using the same | |
de Jong et al. | Scarless Baculovirus Genome Editing Using Lambda-Red Recombineering in E. coli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980144325.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09748839 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12011500734 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2740714 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011535164 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009315471 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/004902 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011001056 Country of ref document: CL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2009748839 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009748839 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009315471 Country of ref document: AU Date of ref document: 20091111 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20117013218 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2405/KOLNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11072225 Country of ref document: CO Ref document number: 14159207 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011114814 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13128629 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0921907 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110510 |